^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MX69-114b

    i
    Other names: MX69-114b
    Company:
    Emory University
    Drug class:
    MDM2 protein degrader
    1year
    A MDM2 degrader inhibits cell proliferation and growth of MDM2-overexpressing acute lymphoblastic leukemia in SCID mice (AACR 2023)
    Importantly, MX69-114b had minimal or no inhibitory effect on normal human hematopoiesis in vitro and was very well tolerated in vivo in animal models. Based on the strong inhibitory and apoptotic activity against MDM2-overexpressing ALL, along with minimal or no toxicity to normal cells/tissues, MX69-114b is a candidate for further development as a novel MDM2-targeted therapeutic drug for refractory ALL.
    Preclinical
    |
    MDM2 (E3 ubiquitin protein ligase)
    |
    MDM2 overexpression
    |
    MX69-114b